Search
Zhixiang Jintai Receives Approval for Salvimimab Injection Clinical Trial in Rabies Exposure
2025-07-29 /
Read about 0 minute
Author：小编
Zhixiang Jintai has announced that its independently developed Salvimimab Injection has secured approval from the National Medical Products Administration (NMPA) to initiate clinical trials for passive immunization against suspected rabies virus exposure in children and adolescents aged 2 to 18. Salvimimab Injection, a recombinant fully human bispecific antibody targeting the rabies virus, falls under Class 1 therapeutic biological products. Despite securing clinical trial approval, the drug must still undergo comprehensive clinical trials and submit a new drug application for marketing approval before it can be officially launched on the market with a drug registration certificate.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
